Neuraly has announced that its investigational NLY01 did not meet the primary study endpoint of improvement in motor symptoms in patients with early, untreated Parkinson’s disease.According to a company release, NLY01 is a long-acting analogue of exendin-4, a glucagon-like peptide-1 receptor agonist. In an ongoing phase 2 trial, NLY01 did not achieve statistically significant change from